VistaGen Therapeutics Inc
NASDAQ:VTGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
US |
|
T
|
TLI Inc
KOSDAQ:062860
|
KR |
|
Vicinity Centres
ASX:VCX
|
AU |
|
P
|
Primo Brands Corp
NYSE:PRMB
|
US |
|
H
|
Hyundai Hyms Co Ltd
KOSDAQ:460930
|
KR |
|
R
|
Robinsons Land Corp
XPHS:RLC
|
PH |
Relative Value
The Relative Value of one VTGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 0.609 USD, VistaGen Therapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
VTGN Competitors Multiples
VistaGen Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
24.1m USD | 30 | -0.5 | 0.7 | 0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |